Plasma and serum concentrations of VEGF-A121, but not of VEGF-A165, increase post-bevacizumab administration.

<h4>Background</h4>VEGF-A concentrations were measured in the blood of bevacizumab-treated cancer patients in previous studies, but a consensus has not formed that would develop VEGF-A into a clinical biomarker. Recently, methods to strictly distinguish between the VEGF-A isoforms have been develope...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Masashi Okawa, Munekazu Yamakuchi, Aryal Bibek, Kazunori Takenouchi, Drew N Maywar, Shingo Yamada, Keiichi Inoue, Kazuhiko Higurashi, Junichi Nakazawa, Masahiro Kawahira, Tomoko Kodama, Kiyonori Tanoue, Yoko Oyama, Sadayuki Higashi, Chieko Fujisaki, Hirohito Hashinokuchi, Akito Tabaru, Hideaki Kanda, Shuji Tachioka, Yutaka Imoto, Teruto Hashiguchi, Yoshiharu Soga
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Public Library of Science (PLoS) 2024-01-01
coleção:	PLoS ONE
Acesso em linha:	https://doi.org/10.1371/journal.pone.0316035
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!